Unity stock has tumbled twice recently, first after Google's Project Genie Reveal, and then after a disappointing earnings report. Project Genie is impressive, but it won't replace video game engines.

Rhode Island is a very particular place. We have unwritten rules, unsung heroes, and under-appreciated places. Diet plans account for staples like doughboys, calamari, chowdah, pizza sticks and awful ...

Hamza is a gaming enthusiast and a Writing Specialist from Pakistan. A firm believer in Keyboard/Mouse supremacy, he will play Tekken with WASD if you let him. He has been writing about games since ...

This article is written by a student writer from the Her Campus at Holy Cross chapter and does not reflect the views of Her Campus. As a Political Science major, all I hear about is how our politics ...

In a heated political environment, it is important to find common ground. There is perhaps no place better than sports. Some say it is all for the love of the game, but the stress of politics and ...

Though Unity claims there's no evidence of impact 'on users or customers.' When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...

For robots to be successfully introduced in a wider range of real-world settings, they should be able to safely and reliably navigate rapidly changing environments. While roboticists and computer ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies. Unity’s restructuring comes along with 36-week results from its phase 2b ...

This program is presented by the Clarke Forum for Contemporary Issues and co-sponsored by the departments of anthropology, American studies, history and geosciences. Phoebe R. Stubblefield, Director ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...